Skip to search formSkip to main contentSkip to account menu

L 869298

Known as: L869,298, L 869,298, L-869298 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Cyclic N-OxidesPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Practical asymmetric synthesis of a potent PDE4 inhibitor via stereoselective enolate alkylation of a chiral aryl-heteroaryl secondary tosylate.
A practical, chromatography-free catalytic asymmetric synthesis of a potent and selective PDE4 inhibitor (L-869,298, 1) is… 
2005
2005
Asymmetric Synthesis of L-869,298, a Potent PDE4 Inhibitor
asymmetric hydrogenation P. D. O’SHEA,* C. CHEN,* W. CHEN, P. DAGNEAU, L. F. FREY, E . J . J . GRABOWSKI, K. M. MARCANTONIO, R. A… 
2005
2005
Practical enantioselective process for a chiral phosphodiesterase-4 inhibitor.
L-869298 is a potent and selective phosphodiesterase-4 (PDE4) inhibitor, which is potentially useful in the treatment of asthma… 
Highly Cited
2003
Highly Cited
2003
Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel…
A SAR study on the tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors related to 1 is described. In addition to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)